Assay Change – illumigene® Group B Strep

Effective Tuesday, August 13th, Women’s Health Laboratories will begin converting our molecular testing approach for the detection of Group B Streptococcus. We will be transitioning from the previous Access Genetics PCR based assay to the FDA-approved illumigene® Group B Streptococcus (GBS). The illumigene® assay uses a combined bacterial culture/nucleic acid amplification approach for the detection of GBS colonization in pregnant women. This approach is the testing approach recommended by the Centers for Disease Control as well as several professional organizations. Following culture for 18-24 hours, the illumigene® GBS Assay uses loop-mediated isothermal nucleic acid amplification technology, specifically targeting the Streptococcus agalactiae genome.

3495 Hacks Cross Rd. / Memphis, TN 38125      
Home | Site Map | Copyright © 2011. Poplar Healthcare. All Rights Reserved.